Researched and fact-checked in-house against primary literature and regulator records. Not reviewed by a named clinician — how we work.
Evidence-rated reference Updated August 2026
We sell nothing. No vendor sponsorship. Editorial policy
pepteyes .com

GHK-Cu vs Palmitoyl Tripeptide-1

The same GHK sequence with two different delivery strategies.

The distinction that mattersSame GHK tripeptide. GHK-Cu carries a copper ion and works partly by delivering copper; palmitoyl tripeptide-1 carries a fatty tail for penetration and delivers no copper.

GHK-Cu Cosmetic IngredientPalmitoyl Tripeptide-1 Cosmetic Ingredient
Evidence rating
3/5 Moderate Evidence rating 3 out of 5: Moderate
3/5 Moderate Evidence rating 3 out of 5: Moderate
Regulatory statusEstablished cosmetic ingredient with human topical data. Injectable use is unapproved and unstudied.Widely used cosmetic ingredient, typically paired with palmitoyl tetrapeptide-7 in commercial formulations.
CategorySkin & CosmeticSkin & Cosmetic
Drug classNaturally occurring copper-binding tripeptideLipidated tripeptide — the GHK sequence conjugated to palmitic acid
RouteTopical (well studied); injectable (not studied)Topical
Half-lifeTopical residence measured in hours; declines with age in plasmaNot applicable — topical
Studied inMultiple controlled topical trials in facial photoaging, wound healing, and hair growth; extensive fibroblast and gene-expression work.Controlled topical studies of the combination product measuring wrinkle depth and dermal density; fibroblast and ex-vivo skin work.
Who should avoid it
  • Wilson disease or copper metabolism disorders (systemic use)
  • Known copper allergy
  • Broken or actively infected skin without medical advice
  • Known ingredient allergy
  • Broken or actively irritated skin
Legal statusLawful as a cosmetic ingredient. Injectable preparations are unapproved.Lawful cosmetic ingredient.

Benefits — GHK-Cu

  • Improved skin firmness and wrinkle depth

    Controlled facial trials with copper-peptide creams showed measurable improvements in wrinkle depth, skin density and elasticity versus vehicle.

  • Wound healing acceleration

    Human and animal studies show faster closure and better-organised collagen deposition in wounds.

  • Collagen and elastin stimulation

    Robust fibroblast data showing upregulation of matrix synthesis.

  • Hair follicle effects

    Small studies suggest increased follicle size and hair density with topical application.

  • Antioxidant and anti-inflammatory activity

    Reduces oxidative damage markers in laboratory models.

Benefits — Palmitoyl Tripeptide-1

  • Wrinkle depth reduction in controlled studies

    Combination products showed measurable improvement in wrinkle depth and skin smoothness versus vehicle over 8–12 weeks.

  • Collagen and matrix stimulation

    Consistent fibroblast data for increased collagen I, III and IV, plus fibronectin and hyaluronic acid.

  • Better penetration than unmodified GHK

    The palmitoyl chain solves the delivery problem that limits most topical peptides.

  • Complementary anti-inflammatory partner

    The paired tetrapeptide-7 targets IL-6-driven matrix degradation, a different mechanism from collagen stimulation.

  • Very well tolerated

    Suitable for sensitive skin and compatible with most other actives.

Risks & cons — GHK-Cu

  • Injectable use has no evidence base

    The credible data is topical. Injecting copper peptides for systemic anti-aging has not been studied and introduces copper-load questions.

  • Copper accumulation concern

    Chronic high-dose systemic copper exposure carries hepatic and neurologic risk; contraindicated in Wilson disease.

  • Skin irritation and contact dermatitis

    Occurs in a minority of topical users, more often at higher concentrations.

  • Incompatibility with vitamin C and some acids

    Direct co-application can destabilise the complex; separate application times are advised.

  • Wide variation in product concentration

    Cosmetic products differ enormously in actual GHK-Cu content and formulation quality.

Risks & cons — Palmitoyl Tripeptide-1

  • Effect sizes are modest

    Real but incremental. It will not approach the results of retinoids at effective concentrations, or procedural treatments.

  • Evidence largely from ingredient suppliers

    Most supporting studies are manufacturer-sponsored, and independent replication is limited.

  • Combination products obscure attribution

    Because it is nearly always sold with tetrapeptide-7, the individual contribution of each peptide is unclear.

  • Concentration rarely disclosed

    Products vary widely and often contain far less than the studied concentration.

  • Requires continuous use

    Benefits regress once application stops.

Infographic for GHK-Cu
Infographic for Palmitoyl Tripeptide-1

A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.